Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
Clasificación en acciones #24601
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Precio por acción
$3.09
Capitalización bursátil
$58.82M
Cambio (1 día)
0.33%
Cambio (1 año)
-73.01%
País
US
Comercio Elicio Therapeutics, Inc. (ELTX)

Categoría

EPS de Elicio Therapeutics, Inc. (ELTX)
EPS a fecha de 2026 TTM: 0
Según los últimos informes financieros y el precio de las acciones de Elicio Therapeutics, Inc., el EPS actual de la empresa (TTM) es 0. Al final del año 2026, la empresa tenía un EPS de 0 igual a al EPS de 2026, que fue de 0.
Historial de EPS de Elicio Therapeutics, Inc. desde 2026 hasta 2026
EPS al final de cada año
Año EPS Cambiar
Not enough data for the provided dates.
EPS de empresas similares o competidoras
Empresa EPS Diferencia de EPS País
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$2.98 -
AU
- -
CH